Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Despite his reputation as a growth investor, Peter Lynch offers valuable insights into dividend stocks, too. These insights are often overlooked by many of us due to his success with high-growth stocks. This article examines two healthcare stalwarts, AbbVie Inc. and Amgen Inc., through the lens of Lynch's approach.

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Should You Invest in AbbVie (ABBV) Based on Bullish Wall Street Views?

Ares Capital

Enterprise Products Partners

AbbVie is a Dividend King that should soon return to growth. Ares Capital is in good shape to continue delivering attractive total returns.

3 "Boring" Stocks That Could Make You Rich

Pfizer

Pfizer and AbbVie face headwinds right now, but their long-term outlooks remain bright. Both stocks trade for a bargain today.

Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now

Duke Energy

Coca-Cola

Philip Morris

Phillips 66

Vici Properties

While it's always important to consider passive-income providers, they often lack an underlying growth impetus, which subsequently makes the concept of high-yield dividend growth stocks so compelling. You can get your growth and also enjoy dividend payments.

Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth

ALLĒ MEMBERS CAN CELEBRATE THE HOLIDAY ALL OF NOVEMBER IRVINE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:  ABBV ), celebrated the fifth annual BOTOX® Cosmetic Day like never before, achieving record-breaking numbers.

Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Gets FDA “Study May Proceed” Notice for Phase IIA Clinical Trial of AL001 a Next-Generation Lithium Therapeutic for Major Depressive Disorder.

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Colgate-Palmolive

Chevron

Emerson Electric

JPMorgan Chase & Co

Kimberly-Clark

Lockheed Martin

Target

While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.

The Best 7 Dividend Stocks to Own in Retirement

Apple

American Express

Bank of America

Blackrock Inc

Citigroup

Crown Castle International

Itau Unibanco Holding S.A.

Microsoft

NIKE

Tesla

Visa

Wells Fargo

Dividend growth companies are an essential part of a risk-adjusted, well-balanced, and extensively diversified dividend income portfolio. I will present you with a list of 10 currently attractive dividend growth companies that have shown an Average Dividend Growth Rate [CAGR] of 10.92% over the past 5 years. Their P/E [FWD] Ratio stands at 21.88 on average, suggesting that their Valuation is attractive, particularly when considering the companies' growth prospects.

Up To 16% Dividend Growth And Yields Reaching 6%: November's Top 10 Dividend Growth Stocks

Johnson & Johnson

PepsiCo

Public Storage

Texas Instruments

Williams

Before extolling the benefits of high-yield blue-chip stocks, it's important to acknowledge the reality that many investors are feeling. Long-term stock investors have had to muddle through challenging macroeconomic headwinds in 2023.

7 High-Yield Blue Chips Suitable for Any Retiree

-     More patients treated with UBRELVY® 100 mg during the prodrome avoided the development of moderate or severe headache within 24 hours post-dose vs. placebo in those who could identify prodrome symptoms that were reliably followed by headache 1 -     UBRELVY is the first and only acute treatment for migraine that has demonstrated data in the prodrome phase in a Phase 3, double-blind, placebo-controlled trial -     AbbVie is the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine NORTH CHICAGO, Ill.

Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine

AbbVie's top-selling drug, Humira, has lost exclusivity, and its sales are falling. Pfizer is seeing lower demand for its blockbuster coronavirus vaccine.

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

BASF SE

B&G Foods

Bayerische Motoren Werke AG

BRT Apartments

Blackstone Group

Cisco Systems

CVS Health

Dominion Energy

Diversified Healthcare Trust

Disney

S&P 500 and Dow Jones dropped for the third straight month in October, just before staging a remarkable reversal in November. Interest rates were kept steady again in a range of 5.25% to 5.5%, and it is uncertain if 2023 will see yet another hike. Net investments of around $1,800 in October, primarily targeting the financial sector and high-yielding BDCs.

My Dividend Stock Portfolio: New October Dividend Record - 98 Holdings With 23 Buys

Allegro MicroSystems

W.W. Grainger

Over the past few weeks, Finbold has unveiled reports exposing the substantial stock market activities of certain US Congress members, some of which resulted in multimillion-dollar profits.

Revealed: Congress' busiest stock traders in the last year

Medtronic

Companies with histories of paying dividends and raising them consistently tend to outperform stocks that don't. Medtronic is a leading manufacturer of medical devices, and its dividend yields 3.9% at recent share prices.

2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade

These dividend stocks each have a solid track record of dividend growth, and their dividend yield tops that of the S&P 500 index. These players also offer promising earnings prospects.

3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing

Eli Lilly

Novo Nordisk

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

4 Large Drug Stocks Likely to Sail Through Industry Woes

ATLANTA--(BUSINESS WIRE)---- $ABBV #505b2_NDA_pathway--Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of a Next-Generation Lithium Therapeutic Drug AL001; Targeting Patients with PTSD.

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

News for AbbVie Stock (ABBV)